Advertisement

Current Bladder Dysfunction Reports

, Volume 13, Issue 4, pp 230–233 | Cite as

A Review of Multiple Sclerosis for Urologists and Urogynecologists with an Emphasis on Management

  • Jaison GrimesEmail author
Neurogenic Bladder (C Powell, Section Editor)
  • 17 Downloads
Part of the following topical collections:
  1. Topical Collection on Neurogenic Bladder

Abstract

Purpose of Review

Multiple sclerosis is a common immune-mediated condition of the central nervous system. It remains one of the most disabling conditions affecting young people, and there is significant cost associated with managing this condition. Revisions of the diagnostic criteria have contributed to better identification and diagnosis of the condition, but consensus approaches to managing the condition are not fully established. Approaches to managing acute demyelination, chronic demyelination, and symptomatic treatments are reviewed.

Recent Findings

The most common treatment for acute demyelination continues to be the use of corticosteroids via the intravenous or oral routes. Duration of corticosteroid treatment is variable, but high dose treatment is commonly administered over 3 to 7 days. There is a growing arsenal of medications to treat chronic demyelination that includes the use of self-administered injections, daily oral immunomodulation, and intravenous infusions each with their own set of pros and cons. While it is important to address both acute and chronic demyelination, symptomatic treatment should always be addressed to increase the overall quality of activities of daily living.

Summary

Individuals with multiple sclerosis are all phenotypically different, and careful consideration should be used to individualize therapy for those living with this disease state. As with other autoimmune conditions, not all patients with multiple sclerosis will require long-term chronic therapy. However, chronic immunomodulatory treatments should be offered to all patients to prevent future disease activity until reliable biomarkers are established. Much remains unknown about the pathophysiology of this condition, but advancements in treatment suggest the future is promising for those affected by this condition.

Keywords

Multiple sclerosis Urologists Urogynecologists Management 

Notes

Compliance with Ethical Standards

Conflict of Interest

Jaison Grimes declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hirtz D, Thurman DJ. How common are the “common” neurologic disorders? Neurology. 2007;68:326–37.CrossRefGoogle Scholar
  2. 2.
    Olek M & Mowry E (2018). Pathogenesis and epidemiology of multiple sclerosis. Up to date.Google Scholar
  3. 3.
    Hartung DM, Bourdette DN, Ahmed SM, Witham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology. 2015;84(21):2185–92.Google Scholar
  4. 4.
    McDonald WI, Compston A. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.CrossRefGoogle Scholar
  5. 5.
    • Polman C, Reingold SC, Banwell B. Diagnostic Criteria for Multiple Sclerosis: 2010 Revision to the McDonald criteria. Ann Neurol. 2011;69:292–302 This article is the most recent attempt to give consensus guidelines for treatment of MS. CrossRefGoogle Scholar
  6. 6.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.Google Scholar
  7. 7.
    Martinelli V, Rocca MA. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology. 2009;73:1842–8.CrossRefGoogle Scholar
  8. 8.
    Le Page E, Veillard D, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-bling, non-inferiority trial. Lancet. 2015;386:974–81.CrossRefGoogle Scholar
  9. 9.
    Thompson AJ, Kennard C. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989;39:969–71.CrossRefGoogle Scholar
  10. 10.
    Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878–86.Google Scholar
  11. 11.
    Rae-Grant A, Day GM, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: American Academy of Neurology. Neurology. 2018;90:777–88.CrossRefGoogle Scholar
  12. 12.
    Heine M, van de Ingrid P (2015). Exercise therapy for fatigue in multiple sclerosis. Cochrane database of systematic reviews.Google Scholar
  13. 13.
    •• Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–63 Good review that demonstrates both oral and IV steroids are effective. CrossRefGoogle Scholar
  14. 14.
    Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep. 2018;18(8):50.Google Scholar
  15. 15.
    Russel R, Black R, & Sherriff JB (2018). Dietary responses to a multiple sclerosis diagnosis: a qualitative study. Eur J Clin Nutr.Google Scholar
  16. 16.
    Lombardi V, De Meirleir K, Subramanian K. Nutritional modulation of the intestinal microbiota: future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease. J Nutr Biochem. 2018;61:1–16.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations